BackgroundThere have been wide variations in the reported prevalence (up to 30%) of autoimmune disorders (AID) in TET patients (pts) in small single-center series. RYTHMIC (Réseau tumeurs THYMiques ...et Cancer) is a French network mandated to systematically discuss every case of TET. A histopathology central review of the samples is performed within a National Histopathological Tumor Board (NHTB). We aimed to assess the prevalence of AID in a large cohort after pathological central review.MethodsRYTHMIC database, hosted by IFCT (French Intergroup of Thoracic Cancerology), prospectively includes all consecutive pts with a diagnosis of TET discussed in French national or regional tumor boards. A expert pathological panel reviews all cases discussed during NHTBs. We analyzed epidemiological, clinical and pathological characteristics of pts.ResultsFrom January 2012 to December 2019, 2909 pts were included in the database. The median age at diagnosis of TET was 60 (range of 14-87), 53.6% were male. About 24% of the pts tumor samples (n=701) were centrally reviewed. In this subgroup of patients, the % of AID was overall similar to the whole cohort, 139/701 (19.8%). Three pts (2%) had more than 1 AID. Among the events, 96 were myasthenia gravis (MG) (69%), 9 Good’s syndrome (6.7%), 5 pure red cell aplasia (3.5%), 7 thyroiditis (5%) and 8 lupus (5.7%). Among pts presenting AID in the cohort (n=701), B2 was the most common subtype before and AB after central review, respectively. Before and after central review, the prevalence of different subtypes is shown in the table.ConclusionsAround 1 out of 5 TET patients present an AID. The highest prevalence of AID after pathological central review was in B3 then B2 and B1 subtypes. Immunotherapy should be restricted to thymic carcinoma where the rate of AID is the lowest (3.3%).
In order to study the secular trend and age and geographic distribution of cervical cancer at the Mexican Institute for Social Security, an ecologic study was carried on. During the last 10 years ...cervical cancer has been the second most common neoplasia, being the leading one in women. For those between 30 and 44 years old it is the third cause of death, and one of the first ten in all age groups until 64. Mortality has shown a stable trend for the last 15 years, in a range from 3.3 to 4.5 deaths per 100,000 inhabitants. Mortality rates increase with age. There is a fine-fold increase in the risk of death for women 40 to 49 years old (CI 95% 4.2-6.4%) and a tenfold increase for those over 80, (CI 95% 7.3-12.6) when taking those under 40 years old as a reference group. In 1989, the cervical cancer incidence was 9.7 cases for each 100,000 person-years. Morbidity and mortality are unequally distributed along the country. There is a need for the development of research in order to know better the occurrence of this disease as well as how known risk factors affect it.
PDF
